Cantor Fitzgerald Upgrades CVS Health (NYSE:CVS) to Overweight

CVS Health (NYSE:CVS) was upgraded by investment analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday, Marketbeat.com reports.

CVS has been the topic of several other research reports. Barclays cut their price target on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Leerink Partners lifted their price target on CVS Health from $51.00 to $55.00 and gave the stock a “market perform” rating in a research report on Tuesday. Royal Bank of Canada cut their price target on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. UBS Group cut their price target on CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, Mizuho dropped their target price on CVS Health from $73.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $70.28.

CVS Health Price Performance

Shares of NYSE CVS opened at $66.35 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The firm has a market capitalization of $83.49 billion, a PE ratio of 16.84, a price-to-earnings-growth ratio of 0.60 and a beta of 0.61. The stock’s 50-day simple moving average is $50.71 and its 200-day simple moving average is $55.94.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. As a group, equities research analysts forecast that CVS Health will post 5.14 EPS for the current fiscal year.

Institutional Trading of CVS Health

A number of institutional investors have recently bought and sold shares of CVS. Norges Bank purchased a new stake in CVS Health during the fourth quarter worth $839,574,000. Davis Selected Advisers boosted its position in CVS Health by 2,998.1% during the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator’s stock worth $511,115,000 after purchasing an additional 11,018,438 shares in the last quarter. Dodge & Cox boosted its position in CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator’s stock worth $3,147,054,000 after purchasing an additional 7,075,209 shares in the last quarter. Pzena Investment Management LLC boosted its position in CVS Health by 49.3% during the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock worth $880,319,000 after purchasing an additional 6,475,271 shares in the last quarter. Finally, Invesco Ltd. boosted its position in CVS Health by 30.1% during the fourth quarter. Invesco Ltd. now owns 18,038,089 shares of the pharmacy operator’s stock worth $809,730,000 after purchasing an additional 4,173,243 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.